Sign inJoin waitlistJoin the waitlist

Gary Burton

Professor of Internal Medicine, Division Chief of Hematology and Oncology, Feist-Weiller Cancer Center · LSU Health Sciences Center

Credentials: · · · ·

History

Division Chief of Hematology and Oncology · LSU Health Sciences Center
Present
LSU Health Sciences Center
Present

Medical Oncology
1981–1983
University of Utah Health
1978–1981
University of Utah School of Medicine
1974–1978

Research

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex…
Journal of Clinical Oncology · 2000 · 753 citations
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior…
Journal of Clinical Oncology · 2002 · 463 citations
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
The Lancet · 2009 · 196 citations

Federico Ampil
34 papers
Glenn Mills
21 papers
Benjamin Li
17 papers
Quyen Chu
13 papers
MH
Mardjohan Hardjasudarma
5 papers
RK
Roger Kim
5 papers · 5 as a resident
Anil Nanda
4 papers
Cherie-Ann Nathan
4 papers
Prakash Peddi
4 papers
Dawn Hershman
3 papers
FA
Fleurette Abreo
3 papers
George Leight
3 papers

Clinical trials

A Study of the Effect of Polyphenon E (Green Tea Extract) on Breast Cancer Progression
Principal investigator · Completed · Phase 2
Louisiana State University Health Sciences Center Shreveport
2004–2013
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Site PI · Recruiting
Wake Forest University Health Sciences
2025–2028
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033